KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $1.3 billion.

  • Royalty Pharma's Net Income towards Common Stockholders fell 44.91% to $444.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 24.00%. This contributed to the annual value of $1.3 billion for FY2024, which is 21.72% down from last year.
  • Per Royalty Pharma's latest filing, its Net Income towards Common Stockholders stood at $1.3 billion for FY2024, which was down 21.72% from $1.7 billion recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Net Income towards Common Stockholders registered a high of $1.7 billion during FY2020, and its lowest value of $230.1 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is $1.1 billion, with a median of $1.3 billion in 2024.
  • As far as peak fluctuations go, Royalty Pharma's Net Income towards Common Stockholders tumbled by 81.46% in 2022, and later spiked by 638.96% in 2023.
  • Yearly analysis of 5 years shows Royalty Pharma's Net Income towards Common Stockholders stood at $1.7 billion in 2020, then fell by 27.07% to $1.2 billion in 2021, then plummeted by 81.46% to $230.1 million in 2022, then spiked by 638.96% to $1.7 billion in 2023, then declined by 21.72% to $1.3 billion in 2024.